Ivan Marazzi, PhD

Locations

Annenberg Building Floor 16 Room 50, 1468 Madison Ave, New York, NY, 10029

Publications

Scopus h-index:18

Article:22

Review Article:5

Comment/Debate:2

Editorial:1

Selected Publications

• Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
• Author Correction: Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4 (Nature, (2022), 606, 7916, (945-952), 10.1038/s41586-022-04844-5)
• Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4
• Emergency drug use in a pandemic: Harsh lessons from COVID-19
• A small nucleosome from a weird virus with a fat genome
• Hnrnpm controls circrna biogenesis and splicing fidelity to sustain cancer cell fitness.
• Unconventional viral gene expression mechanisms as therapeutic targets
• TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
• DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells
• Human Virus Transcriptional Regulators

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Marazzi during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.